Vonvendi Approved for Severe Type 3 von Willebrand Disease

The FDA has approved Vonvendi for routine prophylaxis to reduce the frequency of bleeding episodes in adults with severe Type 3 VWD receiving on-demand therapy.

Related Keywords

, Drug Administration , Takeda Pharmaceutical Company , Heather Dean , Vice President , Franchise Head , Pharmaceutical Company , Accessed January , Pharmaceutical Company Limited ,